Log in

NASDAQ:STSA - Satsuma Pharmaceuticals Stock Price, Forecast & News

-0.07 (-0.36 %)
(As of 01/28/2020 05:46 AM ET)
Today's Range
Now: $19.60
50-Day Range
MA: $17.89
52-Week Range
Now: $19.60
Volume38,000 shs
Average Volume72,929 shs
Market Capitalization$340.57 million
P/E RatioN/A
Dividend YieldN/A
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryRegional Banks
Current SymbolNASDAQ:STSA



Sales & Book Value

Annual SalesN/A



Market Cap$340.57 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals (NASDAQ:STSA) released its quarterly earnings data on Tuesday, November, 12th. The financial services provider reported ($2.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $1.25. View Satsuma Pharmaceuticals' Earnings History.

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Satsuma Pharmaceuticals.

What price target have analysts set for STSA?

3 brokerages have issued 12 month price objectives for Satsuma Pharmaceuticals' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Satsuma Pharmaceuticals' share price to reach $18.00 in the next year. This suggests that the stock has a possible downside of 8.2%. View Analyst Price Targets for Satsuma Pharmaceuticals.

What is the consensus analysts' recommendation for Satsuma Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Satsuma Pharmaceuticals.

Has Satsuma Pharmaceuticals been receiving favorable news coverage?

Media coverage about STSA stock has trended somewhat negative on Tuesday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Satsuma Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news stories about the financial services provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Satsuma Pharmaceuticals.

Who are some of Satsuma Pharmaceuticals' key competitors?

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the folowing people:
  • Mr. John A. Kollins, Pres, CEO & Director (Age 56)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 58)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 54)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 41)
  • Mr. Robert Schultz, VP & Head of CMC (Age 55)

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

When does the company's lock-up period expire?

Satsuma Pharmaceuticals' lock-up period expires on Wednesday, March 11th. Satsuma Pharmaceuticals had issued 5,500,000 shares in its public offering on September 13th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $19.60.

How big of a company is Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals has a market capitalization of $340.57 million. Satsuma Pharmaceuticals employs 11 workers across the globe.View Additional Information About Satsuma Pharmaceuticals.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is http://www.satsumarx.com/.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.

MarketBeat Community Rating for Satsuma Pharmaceuticals (NASDAQ STSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Satsuma Pharmaceuticals and other stocks. Vote "Outperform" if you believe STSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel